Clinical Trials for Eastern Cooperative Oncology Group Performance Status
Currently, there is 1 ongoing clinical trial investigating treatments for arthritis caused by cancer immunotherapy in patients with various performance status levels. This trial is being conducted in France and Sweden, comparing the effectiveness of tocilizumab combined with glucocorticoids versus glucocorticoids alone for managing joint inflammation that develops as a side effect of immune checkpoint inhibitor cancer treatments.
Clinical trial locations
- France
- Sweden
Study on Tocilizumab and Prednisolone for Arthritis Caused by Cancer Immunotherapy in Cancer Patients
This trial focuses on treating arthritis that develops as a side effect of cancer treatment with immune checkpoint inhibitors. These cancer therapies help the immune system fight cancer but can sometimes cause joint inflammation, leading to arthritis.
Main inclusion criteria:
- Participants must be 18 years or older and willing to provide informed consent
- Must have cancer confirmed by a doctor and have developed arthritis as a side effect of immune checkpoint inhibitor treatment
- At least 2 joints must be affected, with a CDAI score (a measure of arthritis activity) greater than 10
- Must have an Eastern Cooperative Oncology Group/World Health Organization Performance Status of 0-1, indicating good general well-being and ability to perform daily activities. A status of 2 is acceptable if it is due to ongoing immune-related side effects
- People already taking glucocorticoids for arthritis can participate if they have been on this treatment for no more than 1 week
- Women of childbearing potential must have a negative pregnancy test and be willing to use effective contraception during the study and for 3 months after the last dose
Main exclusion criteria:
- Patients without cancer confirmed by tissue or cell study
- Patients who have not developed arthritis as a result of immune checkpoint inhibitor treatment
- Patients not within the specified age range
- Patients who are part of a vulnerable population requiring special protection or care
Focus and goal:
The study aims to compare two treatment approaches for arthritis caused by cancer immunotherapy. Participants will be randomly assigned to receive either glucocorticoids alone or a combination of tocilizumab injections and glucocorticoids. The treatment lasts up to 16 weeks, during which the effectiveness of symptom control will be closely monitored. The study will assess various factors including pain levels, joint function, general health, and quality of life to determine which treatment approach is more effective.
Investigational drugs:
The trial uses two main medications. Tocilizumab is administered as an injection under the skin and works by blocking a protein called IL-6 that causes inflammation in the body. By blocking this protein, tocilizumab helps reduce joint inflammation and pain. Glucocorticoids are steroid medications taken orally as tablets that help reduce inflammation and suppress the immune system. The study will determine whether using these medications together is more effective than using glucocorticoids alone.
Summary
Currently, only one clinical trial is available for patients experiencing arthritis as a side effect of cancer immunotherapy. This trial is being conducted in two European countries, France and Sweden, offering opportunities for eligible patients in these locations. The research focuses specifically on comparing tocilizumab combined with glucocorticoids against glucocorticoids alone, representing an important investigation into better management strategies for this treatment-related complication. The trial is particularly relevant for cancer patients with good to moderate performance status who have developed joint inflammation during or after immune checkpoint inhibitor therapy.
